http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw#Head http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw#assertion http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw#provenance http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw#pubinfo http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw#assertion http://purl.obolibrary.org/obo/DOID_2841 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_2841 http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB01136 http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw#association http://www.w3.org/2000/01/rdf-schema#label "Carvedilol tablets are contraindicated in the following conditions: Bronchial asthma or related bronchospastic conditions. Deaths from status asthmaticus have been reported following single doses of carvedilol tablets. Second- or third-degree AV block Sick sinus syndrome Severe bradycardia (unless a permanent pacemaker is in place) Patients with cardiogenic shock or who have decompensated heart failure requiring the use of intravenous inotropic therapy. Such patients should first be weaned from intravenous therapy before initiating carvedilol tablets. Patients with severe hepatic impairment Patients with a history of a serious hypersensitivity reaction (e.g., Stevens-Johnson syndrome, anaphylactic reaction, angioedema) to any component of this medication or other medications containing carvedilol. Bronchial asthma or related bronchospastic conditions ( ) 4 Second- or third-degree AV block ( ) 4 Sick sinus syndrome ( ) 4 Severe bradycardia (unless permanent pacemaker in place) ( ) 4 Patients in cardiogenic shock or decompensated heart failure requiring the use of IV inotropic therapy. ( ) 4 Severe hepatic impairment ( , ) 2.4 4 History of serious hypersensitivity reaction (e.g., Stevens-Johnson syndrome, anaphylactic reaction, angioedema) to any component of this medication or other medications containing carvedilol. ( ) 4" http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw#association https://w3id.org/biolink/vocab/relation https://schema.org/MedicalContraindication https://identifiers.org/drugbank:DB01136 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw#provenance http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw#pubinfo http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw#sig http://purl.org/nanopub/x/hasSignature L5cZAai1q2+VY2pCsUJy3qKqC1hV/0rqAcQrwTIcZba6X8vE3eoP0EyneS/uEpo67OEgxDc2+8bC/aXD7gjHqO0aCObpYt1PgL9B1m1MVU/RK2syb/BuaOZch049NdwzBJDTrAeyiwK9kDwJ/DvdB3cLQHa+DlcPyhKE8CKayCo= http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw http://purl.org/dc/terms/created 2021-08-23T18:53:47.046+02:00 http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAdmYjLFCIsZkATWJjlmp4GMAsTzGMqETvF9G20bw3ZIw https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY